Another GLP-1 pill could be headed for the market soon, according to early clinical trial results.
WEDNESDAY, June 10, 2026 — Another GLP-1 pill could be headed for the market soon, according to early clinical trial results.
“Elecoglipron has the potential to offer people more treatment options that can meet their preferences and support their care goals,” said lead researcher Dr. Vanita Aroda, director of“To date, GLP-1 therapies have largely been limited to injectable or oral peptide formulations, each with inherent delivery and dosing constraint,” she said in a news release. “Rigorous clinical trials … can help us evaluate oral medications that may be just as effective for patients withIn the weight-loss trial, researchers randomly assigned 310 adults to receive either a placebo pill or one of five doses of elecoglipron.
All were either, based on their body mass index . Here's what the trial found: After 36 weeks, patients on the high dose of elecoglipron had lost nearly 12% of their initial body weight, compared with 0.3% in the placebo group.
Overall, about 62% of people on the heavy dose of elecoglipron had lost at least 10% of their body weight by week 36, compared with under 5% of those on placebo.and excess weight to either a placebo tablet or different doses of elecoglipron. After 26 weeks, people taking high-dose elecoglipron had reduced their A1C by nearly 2% on average, compared with 0.2% in the placebo group.
Overall, most people taking high-dose elecoglipron reached their blood sugar targets – 90% got their A1C under 7% and 85% got it under 6.5%. Folks taking elecoglipron for diabetes also lost nearly 8% of their body weight, compared with under 2% in the placebo group. AstraZeneca paid for both clinical trials, which were also presented Monday at the American Diabetes Association annual meeting in New Orleans. Learn to better control your glucose levels by preventing blood sugar swings.
Beware of caffeine, spices, exercise, sleep, alcohol, and stress as they impact blood sugar levels and increase diabetes complications.
Please follow us on Google to support usUnited States Latest News, United States Headlines
Similar News: You can also read news stories similar to this one that we have collected from other news sources.
New Study Suggests No Major Adverse Outcomes With Early GLP-1 Exposure During PregnancyNew research is shedding light on first-trimester GLP-1 exposure during pregnancy — and the findings may offer some reassurance.
Read more »
GLP-1 Users Get Surgery for 'Ozempic Ears' Side EffectAnd you thought “Ozempic butt” was the worst of it.
Read more »
3 ways GLP-1 drugs could be getting betterPharmaceutical giants Pfizer, Roche, Boehringer Ingelheim, and Amgen are among competitors planning to bring improved drugs to the market.
Read more »
Shaquille O’Neal Reveals Obstructive Sleep Apnea Led Him to Take GLP-1sThe 7-foot-1 athlete was diagnosed just after retiring from the NBA.
Read more »